Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer

被引:18
|
作者
Hu, Xin [1 ]
Walker, Mark S. [2 ]
Stepanski, Edward [2 ]
Kaplan, Cameron M. [3 ]
Martin, Michelle Y. [4 ]
Vidal, Gregory A. [5 ,6 ]
Schwartzberg, Lee S. [7 ]
Graetz, Ilana [1 ]
机构
[1] Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, 1518 Clifton Rd NE, Atlanta, GA 30322 USA
[2] ConcertAI, Boston, MA USA
[3] Univ Southern Calif, Gehr Family Ctr Hlth Syst Sci & Innovat, Keck Sch Med, Los Angeles, CA 90007 USA
[4] Univ Tennessee, Ctr Hlth Sci, Coll Med, Ctr Innovat Hlth Equ Res,Dept Prevent Med, Memphis, TN 38163 USA
[5] West Canc Ctr & Res Inst, Germantown, TN USA
[6] Univ Tennessee, Ctr Hlth Sci, Coll Med, Div Hematol & Oncol, Memphis, TN 38163 USA
[7] Renown Inst Canc, Reno, NV USA
关键词
QUALITY-OF-LIFE; AFRICAN-AMERICAN WOMEN; SOCIAL CONSTRUCTION; CARE MONITOR; DISPARITIES; MEDICATION; RACE; CHEMOTHERAPY; VALIDATION; DISTRESS;
D O I
10.1001/jamanetworkopen.2022.25485
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Adjuvant endocrine therapy (AET) reduces breast cancer recurrence, but symptom burden is a key barrier to adherence. Black women have lower AET adherence and worse health outcomes than White women. OBJECTIVE To investigate the association between symptom burden and AET adherence differences by race. DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort study using electronic health records with patient-reported data from a large cancer center in the US. Patients included Black and White women initiating AET therapy for early-stage breast cancer from August 2007 to December 2015 whowere followed for 1 year from AET initiation. Sixty symptoms classified into 7 physical and 2 psychological symptom clusters were evaluated. For each cluster, the number of symptoms with moderate severity at baseline, and symptoms with 3-point or greater increases during AET were counted. Adherence was measured as the proportion of days covered by AET during the first-year follow-up. Multivariable regressions for patients' adherence adjusting for race, symptom measures, sociodemographic characteristics, and clinical characteristics were conducted. Kitagawa-BlinderOaxaca decomposition was used to quantify racial differences in adherence explained by symptoms and patient characteristics. Analyses were conducted from July 2021 to January 2022. EXPOSURES Physical and psychological symptoms at baseline and changes during AET. RESULTS Among 559 patients (168 [30.1%] Black and 391 [69.9%] White; mean [SD] age 65.5 [12.1] years), Black women received diagnoses younger (mean [SD] age at diagnosis, 58.7 [13.7] vs 68.5 [10.0] years old) than White women, with more advanced stages (30 Black participants [17.9%] vs 31 White participants [7.9%] had stage III disease at diagnosis), and lived in areas with fewer adults attaining high school education (mean [SD], 78.8% [ 7.8%] vs 84.0%[9.3%]). AET adherence in the first year was 78.8% for Black and 82.3% for White women. Black women reported higher severity in most symptom clusters than White women. Neuropsychological, vasomotor, musculoskeletal, cardiorespiratory, distress, and despair symptoms at baseline and increases during the follow-up were associated with 1.2 to 2.6 percentage points decreases in adherence, which corresponds to 4 to 9 missed days receiving AET in the first year. After adjusting for psychological symptoms, being Black was associated with 6.5 percentage points higher adherence than being White. CONCLUSIONS AND RELEVANCE In this cohort study, severe symptoms were associated with lower AET adherence. Black women had lower adherence rates that were explained by their higher symptom burden and baseline characteristics. These findings suggest that better symptom management with a focus on psychological symptoms could improve AET adherence and reduce racial disparities in cancer outcomes.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Race differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer.
    Hu, Xin
    Walker, Mark S.
    Stepanski, Edward
    Kaplan, Cameron
    Martin, Michelle Y.
    Vidal, Gregory A.
    Schwartzberg, Lee S.
    Graetz, Ilana
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor-Positive Breast Cancer
    Hu, Xin
    Kaplan, Cameron M.
    Martin, Michelle Y.
    Walker, Mark S.
    Stepanski, Edward
    Schwartzberg, Lee S.
    Vidal, Gregory A.
    Graetz, Ilana
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2023, 32 (02) : 167 - 174
  • [3] Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer
    Chanhyun Park
    Ji-Haeng Heo
    Sanica Mehta
    Sola Han
    Jennifer C. Spencer
    [J]. Clinical Drug Investigation, 2023, 43 : 167 - 176
  • [4] Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer
    Park, Chanhyun
    Heo, Ji-Haeng
    Mehta, Sanica
    Han, Sola
    Spencer, Jennifer C.
    [J]. CLINICAL DRUG INVESTIGATION, 2023, 43 (03) : 167 - 176
  • [5] Differences by race in patient-reported symptoms during chemotherapy among women with early-stage, hormone receptor-positive breast cancer.
    Hu, Xin
    Kaplan, Cameron
    Stepanski, Edward
    Schwartzberg, Lee S.
    Vidal, Gregory A.
    Walker, Mark S.
    Martin, Michelle Y.
    Graetz, Ilana
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Racial differences in adverse sexual symptoms and implications for quality of life and adjuvant endocrine therapy adherence among women with early-stage breast cancer
    Anderson, Janeane N.
    Yang, Freddie
    Hu, Xin
    Vidal, Gregory A.
    Graetz, Ilana
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (09)
  • [7] Adherence to endocrine therapy in patients with hormone receptor-positive early-stage breast cancer: a retrospective study
    Yan, Yi-Dan
    Fu, Jie
    Gu, Zhi-Chun
    Lu, Jin-Song
    Su, Ying-Jie
    Lin, Hou-Wen
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2023, 45 (01) : 184 - 190
  • [8] Adherence to endocrine therapy in patients with hormone receptor-positive early-stage breast cancer: a retrospective study
    Yi-Dan Yan
    Jie Fu
    Zhi-Chun Gu
    Jin-Song Lu
    Ying-Jie Su
    Hou-Wen Lin
    [J]. International Journal of Clinical Pharmacy, 2023, 45 : 184 - 190
  • [9] The postmenopause: adjuvant endocrine therapy at an early stage of hormone receptor-positive breast cancer
    Brucker, S.
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 (08) : 847 - 851
  • [10] Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer
    Jennifer C. Livaudais
    Dawn L. Hershman
    Laurel Habel
    Lawrence Kushi
    Scarlett Lin Gomez
    Christopher I. Li
    Alfred I. Neugut
    Louis Fehrenbacher
    Beti Thompson
    Gloria D. Coronado
    [J]. Breast Cancer Research and Treatment, 2012, 131 : 607 - 617